<DOC>
	<DOCNO>NCT02754037</DOCNO>
	<brief_summary>The goal study evaluate non-invasive image technique determine liver steatosis ( fat ) , inflammation ( abnormal tissue swell ) , fibrosis ( abnormal tissue scar ) .In addition , study group use test measure include personal demographic , laboratory blood test result , image measurement determine severity NAFLD ( non-alcoholic fatty liver disease ) , NASH ( non-alcoholic steatohepatitis ) , inflammation , fibrosis .</brief_summary>
	<brief_title>Non-Invasive Evaluation Liver Steatosis , Inflammation Fibrosis</brief_title>
	<detailed_description>The study group propose evaluate role KBD FDG-PET determination steatohepatitis combination MRI detection , differentiation quantitation liver steatosis , steatohepatitis fibrosis correlation liver biopsy . Patient enrol already liver biopsy undergo liver biopsy part clinical care determine provider get biopsy solely enrol study . Current treatment option patient liver biopsy perform limited lifestyle change vitamin E patient without diabetes .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>1 . Patients &gt; 18 year age 2 . Patients liver biopsy standard care fatty liver disease risk factor NASH . Liver biopsy need within 6 month plan image . 3 . Patients undergo bariatric surgery liver biopsy standard care . 4 . Ability provide inform consent . 1 . History alcohol abuse , chronic hepatitis B C , chronic liver disease nonalcoholic fatty liver disease . 2 . Pregnant woman 3 . Prisoners 4 . Claustrophobic MRI 5 . Allergic FDG dye 6 . Patients unable lie scanner one hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>